Is The Bad News Priced Into Nike Stock Now?
Despite its dominance in the athletic shoe and apparel industry,…
Sell
21
ARMP Quote, Financials, Valuation and Earnings
Last price:
$1.29
Seasonality move
:
1.78%
Day range:
$1.15 - $1.34
52-week range:
$1.15 - $3.85
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
478.46x
P/B ratio:
--
Volume:
74K
Avg. volume:
17.6K
1-year change:
-63.84%
Market cap:
$47.8M
Revenue:
--
EPS (TTM):
-$1.32
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Armata Pharmaceuticals has 430.3% upside to fair value with a price target of $7.00 per share.
ARMP vs. S&P 500
-
Over the past 5 trading days, Armata Pharmaceuticals has underperformed the S&P 500 by -17.27% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Armata Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Armata Pharmaceuticals has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Armata Pharmaceuticals reported revenues of --.
Earnings Growth
-
Armata Pharmaceuticals has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Armata Pharmaceuticals reported earnings per share of -$0.23.
Enterprise value:
132.9M
EV / Invested capital:
--
Price / LTM sales:
478.46x
EV / EBIT:
--
EV / Revenue:
1,155.31x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.37x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$36.9M | -$40.9M | -$42.4M | -$9.6M | -$10.5M | |
| EBITDA | -$36M | -$65.4M | -$6.9M | -$18.1M | $6.3M | |
| Diluted EPS | -$1.09 | -$1.98 | -$1.32 | -$0.55 | -$0.23 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $10.8M | $15M | $27M | $19.2M | $11.3M | |
| Total Assets | $39.5M | $69.8M | $95.8M | $98.4M | $86.4M | |
| Current Liabilities | $6.7M | $4.8M | $24.9M | $16.5M | $48.2M | |
| Total Liabilities | $20.7M | $44.4M | $59.8M | $130.4M | $134.5M | |
| Total Equity | $18.9M | $25.4M | $36.1M | -$32.1M | -$48M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$32.5M | -$47.4M | -$37.6M | -$8.1M | -$7.9M | |
| Cash From Investing | -$2.2M | -$8.1M | -$1.9M | -$2.4M | $77K | |
| Cash From Financing | $44M | $54M | $35M | -$43K | -- | |
| Free Cash Flow | -$34.7M | -$55.6M | -$39.4M | -$10.5M | -$7.9M | |
ARMP
Sector
Market Cap
$47.8M
$35.9M
Price % of 52-Week High
34.29%
43.21%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.91%
1-Year Price Total Return
-63.84%
-43.29%
Beta (5-Year)
0.914
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.51
200-day SMA
Sell
Level
$2.29
Bollinger Bands (100)
Sell
Level
1.82 - 2.28
Chaikin Money Flow
Sell
Level
-116.5M
20-day SMA
Sell
Level
$1.78
Relative Strength Index (RSI14)
Sell
Level
23.68
ADX Line
Sell
Level
16.46
Williams %R
Buy
Level
-85.2174
50-day SMA
Sell
Level
$1.94
MACD (12, 26)
Sell
Level
-0.17
25-day Aroon Oscillator
Sell
Level
-36
On Balance Volume
Neutral
Level
66.7M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
Stock Forecast FAQ
In the current month, ARMP has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ARMP average analyst price target in the past 3 months is $7.00.
-
Where Will Armata Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Armata Pharmaceuticals share price will rise to $7.00 per share over the next 12 months.
-
What Do Analysts Say About Armata Pharmaceuticals?
Analysts are divided on their view about Armata Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Armata Pharmaceuticals is a Sell and believe this share price will drop from its current level to $7.00.
-
What Is Armata Pharmaceuticals's Price Target?
The price target for Armata Pharmaceuticals over the next 1-year time period is forecast to be $7.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ARMP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Armata Pharmaceuticals is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of ARMP?
You can purchase shares of Armata Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Armata Pharmaceuticals shares.
-
What Is The Armata Pharmaceuticals Share Price Today?
Armata Pharmaceuticals was last trading at $1.29 per share. This represents the most recent stock quote for Armata Pharmaceuticals. Yesterday, Armata Pharmaceuticals closed at $1.32 per share.
-
How To Buy Armata Pharmaceuticals Stock Online?
In order to purchase Armata Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is LUV Stock a Buy, Sell or Hold?
Southwest Airlines (NYSE:LUV) is one of America’s major air transportation…
Should I Buy Alcoa Stock?
Alcoa (AA) finds itself in an interesting position in early…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 33x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
44
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
24
DPST alert for Apr 4
Direxion Daily Regional Banks Bull 3X Shares [DPST] is down 31.13% over the past day.
Sell
9
FIVE alert for Apr 4
Five Below [FIVE] is down 27.86% over the past day.
Sell
10
COHR alert for Apr 4
Coherent [COHR] is down 20.24% over the past day.
